#sareptatherapeutics — Public Fediverse posts

https://www.europesays.com/ch/132431/ Novartis (NVS) Suffers its Third Drug Trial Setback in a Week, and its Worst Trading Day in Years #AnnualSales #AnnualSalesGrowth #DyneTherapeutics #Novartis #NovartisAG #PipelineFailures #SareptaTherapeutics

https://www.europesays.com/ch/130386/ StockWatch: Novartis Loses More than Market Value After Phase III Failure #ArrowheadPharmaceuticals #ConjugateVaccine #DuchenneMuscularDystrophy #Dyne101 #EntradaTherapeutics #GenEdge #IndustryNews #MultipleSclerosis #news #Novartis #pepgen #PgnEdodm1 #PhaseIiiClinicalTrials(drugDevelopment) #Remodel1 #Remodel2 #RNA #SareptaTherapeutics #Srp1003 #topics #TranslationalMedicine #VertexPharmaceuticals #Vx670

https://www.europesays.com/ch/86498/ Roche to launch another Elevidys study, eying EU approval #Cell&GeneTherapy #Duchenne #DuchenneMuscularDystrophy(DMD) #Elevidys #EuropeanMedicinesAgency #FiercePharmaHomepage #GeneTherapy #Pharma #Roche #SareptaTherapeutics

https://www.europesays.com/ch/62092/ Sarepta swings to Q1 2026 profit on Roche revenue #DuchenneMuscularDystrophy #Elevidys #NonGAAPNetIncome #Q12026Earnings #QuarterlyResults #Roche #RocheCollaboration #SareptaTherapeutics #SRPT

https://www.europesays.com/ch/50047/ Roche to start new Elevidys study following setback in Europe #DuchenneMuscularDystrophy #DuchennePatients #Europe #GeneTherapy #RegulatoryApproval #Roche #SareptaTherapeutics #StudyResults

https://www.europesays.com/ch/26293/ Oligonucleotides Global Markets, 2022-2024 & 2025-2030, Profiles of Major Players #AlnylamPharmaceuticals #AntisenseOligonucleotides #CompoundAnnualGrowthRate #GlobalMarket #GlobalMarkets #JazzPharmaceuticals #Novartis #Oligonucleotides #SareptaTherapeutics

https://www.europesays.com/uk/570996/ Sarepta Announces FDA’s Approval of Updated ELEVIDYS Prescribing Information #AcuteLiverFailure #AmbulatoryPatients #DMDGene #DuchenneMuscularDystrophy #ELEVIDYS #Health #IntravenousInfusion #LiverInjury #Medication #PrescribingInformation #SareptaTherapeutics #UK #UnitedKingdom

Sarepta Announces FDA’s Approval of Updated ELEVIDYS Prescribing Information

CAMBRIDGE, Mass., November 14, 2025–(BUSINESS WIRE)–Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases,…
#NewsBeep #News #Medication #acuteliverfailure #ambulatorypatients #CA #Canada #DMDgene #duchennemusculardystrophy #ELEVIDYS #Health #intravenousinfusion #Liverinjury #prescribinginformation #sareptatherapeutics
https://www.newsbeep.com/ca/283661/

Sarepta Announces FDA’s Approval of Updated ELEVIDYS Prescribing Information

CAMBRIDGE, Mass., November 14, 2025–(BUSINESS WIRE)–Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for …
#NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Medication #acuteliverfailure #ambulatorypatients #DMDgene #duchennemusculardystrophy #ELEVIDYS #Health #intravenousinfusion #Liverinjury #prescribinginformation #SareptaTherapeutics
https://www.newsbeep.com/us/292160/

Sarepta Announces FDA’s Approval of Updated ELEVIDYS Prescribing Information

CAMBRIDGE, Mass., November 14, 2025–(BUSINESS WIRE)–Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases,…
#NewsBeep #News #Medication #acuteliverfailure #ambulatorypatients #DMDgene #duchennemusculardystrophy #ELEVIDYS #Health #intravenousinfusion #Liverinjury #prescribinginformation #sareptatherapeutics #UK #UnitedKingdom
https://www.newsbeep.com/uk/263365/

https://www.europesays.com/ie/181196/ Sarepta Announces FDA’s Approval of Updated ELEVIDYS Prescribing Information #AcuteLiverFailure #AmbulatoryPatients #DMDGene #DuchenneMuscularDystrophy #Éire #ELEVIDYS #Health #IE #IntravenousInfusion #Ireland #LiverInjury #Medication #PrescribingInformation #SareptaTherapeutics

Evolent Health, West Pharmaceutical Services, Myriad Genetics, Tandem Diabetes, and Integra LifeSciences Shares Are Falling, What You Need To Know

A number of healthcare stocks fell in the afternoon session after…
#NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Genetics #analysisreport #ElevanceHealth #HealthcareTechnology #IntegraLifeSciences #marketsentiment #MyriadGenetics #SareptaTherapeutics #Science #stockmarket #WestPharmaceuticalServices
https://www.newsbeep.com/us/19912/

After full approval, Sarepta lays out its next moves—Zealand Pharma brings in $1B to drive development of obesity drugs —Sanofi seeks initial offers for Its $20 billion consumer arm—http://bit.ly/w28kSd #sareptatherapeutics #dmd #obesity #zealandpharma #funding #consumerhealth #sanofi #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Alphabet's quantum spinoff starts working with AstraZeneca, Sanofi to accelerate R&D — Is this a sign that Leqembi could obtain FDA approval next month? -- Sarepta prices Duchenne gene therapy at $3.2M -- See more on our front page news http://bit.ly/w28kSd #alphabet #artificialintelligence #ai #astrazeneca #sanofi #researchanddevelopment #drugdiscovery #alzheimers #biogen #eisai #fda #genetherapy #dmd #sareptatherapeutics #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

FTC probes Abbott for allegedly colluding on bids for state contracts — FDA delays decision on Duchenne gene therapy and considers narrower approval --How Vivek Ramaswamy helped make Martin Shkreli the ‘pharma bro’ -- See more on our front page news http://bit.ly/w28kSd #FTC #collusion #statecontracts #abbottlabs #fda #DMD #sareptatherapeutics #vivekramaswamy #martinshkreli #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma